Skip to content

Evaluation of Self-assembling Peptides Versus Amorphous Calcium Phosphate in the Treatment of White Spot Lesions

Evaluation of Self Assembling Peptides Versus Amorphous Calcium Phosphate in the Treatment of White Spot Lesions; Split Mouth Randomized Clinical Trial

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07146464
Enrollment
18
Registered
2025-08-28
Start date
2024-03-27
Completion date
2026-06-30
Last updated
2025-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dental Caries Tooth Demineralization, Post-Orthodontic Esthetic Defects

Keywords

White Spot Lesions - Enamel Demineralization - Self-Assembling Peptides - Casein Phosphopeptide-Amorphous Calcium Phosphate

Brief summary

This clinical trial aims to compare the effectiveness of two remineralizing treatments for white spot lesions (WSLs) on the enamel surfaces of the front teeth. WSLs are early signs of tooth decay, often appearing after orthodontic treatment with braces. These white spots may persist for years and affect the esthetic appearance of teeth. The study will include male and female patients aged 15 to 25 who have at least one early carious lesion (ICDAS scores 1 or 2) on each side of their upper or lower front teeth. The purpose is to determine which treatment - Self-Assembling Peptides (SAP P11-4, Curodont Repair™) or Casein Phosphopeptide-Amorphous Calcium Phosphate (CPP-ACP, MI Varnish™) - is more effective in improving the color and reducing the size of these lesions. Researchers will use a split-mouth design, where each patient receives both treatments - one on each side of the mouth. Standardized digital photographs will be taken before and after treatment to assess color changes and lesion size. Patients will also rate their satisfaction with the appearance of their teeth after treatment. The main questions the study will answer are: Does SAP P11-4 improve the color of white spot lesions more effectively than CPP-ACP? Is there a noticeable difference in lesion size reduction between the two treatments? How satisfied are patients with the outcomes of each treatment? Participants will be followed up at 3, 6, and 9 months after treatment. The results aim to guide clinicians toward the most effective treatment to improve the appearance of white spot lesions in young patients after orthodontic care.

Detailed description

White spot lesions (WSLs) are early signs of tooth decay that appear as milky white spots on tooth enamel, especially common after wearing braces. These lesions can last for many years and negatively affect appearance, especially on front teeth. This study investigates two promising treatment options to reverse or reduce the appearance of WSLs. Study Design This is a randomized, split-mouth, double-blinded clinical trial conducted at the Operative Dentistry Department, Faculty of Dentistry, Ain Shams University. The trial includes patients between the ages of 15 and 25 with visible white spot lesions on both sides of their front teeth (ICDAS scores 1-2). Each patient will receive: SAP P11-4 (Curodont Repair) on one side of the mouth. CPP-ACP (MI Varnish) on the other side. The split-mouth design helps reduce differences between participants and improves the reliability of the results. Intervention Procedure Participants will undergo: Initial oral hygiene instructions and professional cleaning. Standardized digital and cross-polarized photography of the teeth. Treatment application according to manufacturer instructions: SAP P11-4 is applied twice (at baseline and 3 months), after cleaning and etching the enamel surface. CPP-ACP is also applied twice (at baseline and 3 or 6 months), with post-application care instructions (avoid brushing or eating for 4 hours). Outcome Measures Primary outcome: Change in color of the white spot lesions over 9 months, measured using digital photography and color analysis software (eLAB-prime). Secondary outcomes: Change in lesion size. Visual scoring using the ICDAS II system. Patient satisfaction with the treatment results, collected through a questionnaire. The study aims to determine which treatment is more effective at improving the appearance and reducing the visibility of WSLs, with the goal of guiding future esthetic dental care.

Interventions

OTHERSelf-Assembling Peptide P11-4 Self-Assembling Peptide P11-4 is a biomimetic material applied topically to white spot lesions on the enamel. It diffuses into the lesion body and forms a three-dimension

Intervention: Self-Assembling Peptide P11-4 Intervention Description: Self-Assembling Peptide P11-4 (SAP P11-4) is a synthetic peptide designed to mimic natural enamel matrix proteins. It is applied to cleaned, etched enamel surfaces with white spot lesions. The peptide diffuses into the subsurface lesion and self-assembles into a 3D scaffold that promotes nucleation and growth of hydroxyapatite crystals. In this study, it is applied at baseline and re-applied after 3 months. The product used is Curodont™ Repair. Intervention: Casein Phosphopeptide-Amorphous Calcium Phosphate (CPP-ACP) Intervention Description: CPP-ACP is a milk-derived peptide complex that stabilizes calcium and phosphate ions in an amorphous form. When applied to enamel surfaces, it delivers these ions to promote remineralization of white spot lesions. In this study, MI Varnish™ is used as the source of CPP-ACP. The varnish is stirred and applied as a thin, uniform layer to cleaned tooth surfaces at baseline and

Sponsors

Ain Shams University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

The study is described as double-blinded, meaning: Participants do not know which treatment is applied to which side. Outcome Assessors (those evaluating lesion color/size from photographs and ICDAS scores) are also blinded to group assignment. the Principal Investigator are not blinded, as they apply the interventions and know the treatment allocation during the procedure.

Intervention model description

This is a split-mouth, double-blinded, randomized controlled trial using a crossover assignment model. Each participant receives both interventions - Self-Assembling Peptides (SAP P11-4) on one side of the anterior teeth and Casein Phosphopeptide-Amorphous Calcium Phosphate (CPP-ACP) on the opposite side. This design minimizes inter-subject variability and allows within-subject comparison of treatment outcomes.

Eligibility

Sex/Gender
ALL
Age
15 Years to 25 Years
Healthy volunteers
No

Inclusion criteria

* Age between 15 and 25 years * Presence of at least one tooth on each side of the anterior region (from right canine to left canine) affected by early carious lesions (ICDAS II code 1 or 2) * Lesion size and form must be fully visible and accessible * Willing and able to attend all study visits and follow instructions * Good general health and oral hygiene * Not taking any medication that affects salivary flow * Provided written informed consent

Exclusion criteria

* Evidence of tooth erosion * Prior fluoride varnish application before study treatment * Hypoplastic enamel defects or multiple restorations on facial surfaces of anterior teeth * High caries risk patients * Known or suspected allergy to milk proteins * Use of medications affecting salivary flow

Design outcomes

Primary

MeasureTime frameDescription
Change in white spot lesion color using standardized cross-polarized photography and digital color analysisBaseline, 3 months, 6 months, and 9 monthsThe primary outcome is the change in the color of enamel white spot lesions, assessed through standardized digital photographs taken at baseline and at 3, 6, and 9 months. Images will be analyzed using eLAB-prime software for objective color quantification.

Secondary

MeasureTime frameDescription
Change in lesion size of white spot lesions based on standardized clinical photographsBaseline, 3 months, 6 months, and 9 monthsLesion size will be evaluated using standardized digital photographs taken at baseline and at 3, 6, and 9 months. Photographs will be used to measure lesion dimensions and determine any reduction or progression in size over time.

Countries

Egypt

Contacts

Primary ContactAmany yasser mohamed, B.D.S., M.Sc.
amany-mohamed@dent.asu.edu.eg01002229647

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026